Co-Authors
This is a "connection" page, showing publications co-authored by MADELEINE DUVIC and MICHAEL TETZLAFF.
Connection Strength
2.655
-
Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877.
Score: 0.171
-
Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018 11; 183(3):428-444.
Score: 0.161
-
Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol. 2017 12 01; 153(12):1302-1306.
Score: 0.153
-
TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform. Front Med (Lausanne). 2017; 4:153.
Score: 0.151
-
Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. J Cutan Med Surg. 2017 Nov/Dec; 21(6):568-571.
Score: 0.149
-
Prim?r kutane CD30(+) lymphoproliferative Erkrankungen. J Dtsch Dermatol Ges. 2016 Aug; 14(8):767-84.
Score: 0.140
-
Primary cutaneous CD30(+) lymphoproliferative disorders. J Dtsch Dermatol Ges. 2016 Aug; 14(8):767-82.
Score: 0.140
-
A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 Feb; 16(2):e15-9.
Score: 0.133
-
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol. 2015 Nov 10; 33(32):3759-65.
Score: 0.131
-
Reed syndrome presenting with leiomyosarcoma. JAAD Case Rep. 2015 May; 1(3):150-2.
Score: 0.129
-
Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer. 2015 Jun 15; 121(12):1993-2003.
Score: 0.127
-
Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol. 2015 Apr; 46(4):558-69.
Score: 0.125
-
Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol. 2014 Jul; 36(7):557-61.
Score: 0.121
-
T-cell receptor-? in gamma-delta phenotype cutaneous T-cell lymphoma can be accompanied by atypical expression of CD30, CD4, or TCR?F1 and an indolent clinical course. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):e195-200.
Score: 0.121
-
Bi-clonal, multifocal primary cutaneous marginal zone B-cell lymphoma: report of a case and review of the literature. J Cutan Pathol. 2012 Sep; 39(9):866-71.
Score: 0.106
-
Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders? Virchows Arch. 2021 Aug; 479(2):377-383.
Score: 0.048
-
The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and S?zary Syndrome: A Multi-institutional and International Pathology Study. Am J Surg Pathol. 2018 06; 42(6):726-734.
Score: 0.040
-
Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. Oncoimmunology. 2018; 7(8):e1467856.
Score: 0.040
-
Differential expression of CCR4 in primary cutaneous gamma/delta (?/d) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. J Dermatol Sci. 2018 Jan; 89(1):88-91.
Score: 0.038
-
Immunophenotypic Shifts in Primary Cutaneous ?d T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol. 2017 Apr; 41(4):431-445.
Score: 0.037
-
Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. Oncoimmunology. 2017; 6(5):e1306618.
Score: 0.036
-
Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (?d) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous ?d T-Cell Lymphomas. Am J Surg Pathol. 2017 Feb; 41(2):204-215.
Score: 0.036
-
Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. Mod Pathol. 2017 05; 30(5):761-772.
Score: 0.036
-
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb; 44(2):158-176.
Score: 0.036
-
Primary Cutaneous Gamma-Delta (?/d) T-cell Lymphoma: An Unusual Case With Very Subtle Histopathological Findings. Am J Dermatopathol. 2016 10; 38(10):e147-9.
Score: 0.035
-
Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 Dec; 43(12):1161-1166.
Score: 0.035
-
BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 2016 Apr; 50:79-89.
Score: 0.033
-
Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med. 2015 Sep; 4(9):1440-7.
Score: 0.032
-
Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol. 2014 Mar; 41(3):326-8.
Score: 0.029
-
The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis. J Cutan Pathol. 2014 Feb; 41(2):88-100.
Score: 0.029
-
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014 Mar; 53(3):376-84.
Score: 0.028
-
Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am J Dermatopathol. 2013 Feb; 35(1):125-8.
Score: 0.027